MedTrace Logo

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

NCT03894891 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-12-20

Study results available
· View outcomes & findings →

Summary

This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.

Conditions

Interventions

DRUG

Nivolumab

Nivolumab is a type of immunotherapy.

DRUG

Cisplatin

Cisplatin is a chemotherapy drug.

DRUG

Docetaxel

Docetaxel is a chemotherapy drug.

RADIATION

Intensity-modulated radiotherapy

IMRT is definitive treatment for head and neck cancer.

Sponsors & Collaborators

Principal Investigators

  • Robert Haddad, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2022-10-31
Completion
2022-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894891 on ClinicalTrials.gov